Order Sucraid®
Important Safety Information
Prescribing Information
Patient Site

Sucraid® treats sucrase deficiency caused by Congenital Sucrase-Isomaltase Deficiency (CSID)

Do you have patients suffering with unresolved bloating, gas, abdominal pain, diarrhea, or nausea? Could it be sucrase deficiency caused by CSID?

Download the Sucraid®
4-Day Trial Rx Form

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
Do you have patients with unresolved bloating, gas, abdominal pain, diarrhea, or nausea?

Could it be sucrase deficiency caused by CSID?

CSID is largely a clinical diagnosis. Did you rule out other underlying conditions and surgical procedures where CSID may not be the primary cause of symptoms?

Consider a 4-Day Trial of Sucraid® at No Cost

In a clinical trial, 81% of patients became asymptomatic* with Sucraid®.1

*Patients who took Sucraid® with each meal were considered asymptomatic if they reported no watery stools and no or mild GI symptoms (gas, bloating, nausea, vomiting, abdominal cramps) for at least 7 of the 10 study days.

  1. Treem WR, McAdams L, Stanford L, Kastoff G, Justinich C, Hyams J. Sacrosidase Therapy for Congenital Sucrase-Isomaltase Deficiency. J Pediatr Gastroenterol Nutr. 1999;28(2):137-142. doi:10.1097/00005176-199902000-00008
How Sucraid® works

Sucraid®: The mechanism of action

The active ingredient in Sucraid® is sacrosidase, which is a sucrase enzyme replacement. It splits sucrose into glucose and fructose, which facilitates absorption of both into the bloodstream from the small intestine.

Therapeutic Response Trial

Sucraid® 4-Day Trial offers eligible patients a short therapeutic trial of Sucraid® to assess response in patients clinically diagnosed with sucrase deficiency caused by Congenital Sucrase-Isomaltase Deficiency (CSID).

Download the Sucraid®
4-Day Trial Rx Form

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

Call the specialty pharmacy for information about Sucraid®

1-833-800-0122

Important Safety Information for Sucraid® (sacrosidase) Oral Solution
Indication

Sucraid® (sacrosidase) Oral Solution is indicated for the treatment of sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID), in adult and pediatric patients 5 months of age and older.

Contraindication

Sucraid® is contraindicated in patients known to be hypersensitive to yeast, yeast products, glycerin (glycerol), or papain.

Warnings, Precautions, and Additional Important Safety Information
  • Severe Hypersensitivity Reactions
    Severe hypersensitivity reactions, including wheezing, difficulty breathing, rash, pruritis, and swelling of the face, lips, mouth, or tongue have been reported with administration of Sucraid®. Sucraid® contains papain, which is associated with hypersensitivity reactions.
  • Increased Blood Glucose Concentration in Patients With Diabetes Mellitus
    Sucraid® enables the products of sucrose hydrolysis, glucose and fructose, to be absorbed and may increase blood glucose concentrations. Monitor blood glucose concentrations and adjust the diet accordingly for patients with diabetes mellitus.
  • Dietary Starch Restriction
    Sucraid® does not replace isomaltase. Therefore, patients may still experience symptoms of CSID while taking Sucraid®. Consider dietary starch restriction in addition to Sucraid®, especially in patients in whom symptoms are not adequately controlled by Sucraid®.
  • Adverse reactions as a result of taking Sucraid® may include worse abdominal pain, vomiting, nausea, diarrhea, constipation, difficulty sleeping, headache, nervousness, and dehydration.
  • The effects of Sucraid® have not been evaluated in patients with secondary (acquired) disaccharidase deficiency.
  • DO NOT HEAT SOLUTIONS CONTAINING SUCRAID®. Do not put Sucraid® in warm or hot fluids. Do not reconstitute or consume Sucraid® with fruit juice since the acidity of the juice may reduce the enzyme activity of Sucraid®. Half of the reconstituted Sucraid® should be taken at the beginning of the meal or snack and the other half during the meal or snack.
  • Sucraid® should be refrigerated at 36°F-46°F (2°C-8°C) and should be protected from heat and light; single-use containers can be removed from refrigeration and stored at 59°F-77°F (15°C-25°C) for up to 3 days (72 hours). Refer to Instructions for Use for full information on how to take Sucraid®.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.

IMPORTANT SAFETY INFORMATION:

Important Safety Information for Sucraid® (sacrosidase) Oral Solution

Indication

Sucraid® (sacrosidase) Oral Solution is indicated for the treatment of sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID), in adult and pediatric patients 5 months of age and older.

Contraindication

Sucraid® is contraindicated in patients known to be hypersensitive to yeast, yeast products, glycerin (glycerol), or papain.

Warnings, Precautions, and Additional Important Safety Information

  • Severe Hypersensitivity Reactions
    Severe hypersensitivity reactions, including wheezing, difficulty breathing, rash, pruritis, and swelling of the face, lips, mouth, or tongue have been reported with administration of Sucraid®. Sucraid® contains papain, which is associated with hypersensitivity reactions.
  • Increased Blood Glucose Concentration in Patients With Diabetes Mellitus
    Sucraid® enables the products of sucrose hydrolysis, glucose and fructose, to be absorbed and may increase blood glucose concentrations. Monitor blood glucose concentrations and adjust the diet accordingly for patients with diabetes mellitus.
  • Dietary Starch Restriction
    Sucraid® does not replace isomaltase. Therefore, patients may still experience symptoms of CSID while taking Sucraid®. Consider dietary starch restriction in addition to Sucraid®, especially in patients in whom symptoms are not adequately controlled by Sucraid®.
  • Adverse reactions as a result of taking Sucraid® may include worse abdominal pain, vomiting, nausea, diarrhea, constipation, difficulty sleeping, headache, nervousness, and dehydration.
  • The effects of Sucraid® have not been evaluated in patients with secondary (acquired) disaccharidase deficiency.
  • DO NOT HEAT SOLUTIONS CONTAINING SUCRAID®. Do not put Sucraid® in warm or hot fluids. Do not reconstitute or consume Sucraid® with fruit juice since the acidity of the juice may reduce the enzyme activity of Sucraid®. Half of the reconstituted Sucraid® should be taken at the beginning of the meal or snack and the other half during the meal or snack.
  • Sucraid® should be refrigerated at 36°F-46°F (2°C-8°C) and should be protected from heat and light; single-use containers can be removed from refrigeration and stored at 59°F-77°F (15°C-25°C) for up to 3 days (72 hours). Refer to Instructions for Use for full information on how to take Sucraid®.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.

Coming soon.